Orforglipron
Also known as: LY3502970, OWL833
Popular For
Oral weight loss option, diabetes, convenience
Key Facts: Orforglipron
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- NDA Under Review - FDA decision expected April 10, 2026
- Administration
- Oral tablet daily
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- Human Trials
- Duration
- Long-term use expected
Mechanism of Action
Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide.
Research Summary
ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025. Selected for FDA National Priority Voucher program but review was delayed to April 2026.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Not yet FDA approved (decision expected April 2026). If approved, Lilly has announced LillyDirect pricing: $149-$399/month self-pay depending on dose.
Research Dosingⓘ
Scientific studies
Doses from clinical trials
Doses from Studies
12-45mg once daily
Various doses in trials
Duration
Long-term use expected
Administration
Oral tablet daily
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Diarrhea (19-26%)
- ●Nausea (13-18%)
- ●Vomiting
- ●GI events mild-moderate
- ●Pulse increase
- ●Investigational - not yet approved
References
Related Peptides
Peptides commonly compared with Orforglipron or used in similar applications.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossRetatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Weight LossCagriSema
Clinical TrialsA combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossDulaglutide
FDAAn FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Weight LossLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on Orforglipron research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.